Cerenkov luminescence imaging of medical isotopes.
Cerenkov luminescence imaging of medical isotopes.
复制标题
DOI：
10.2967/jnumed.110.076521
复制
发表时间：
2010-07
期刊：
影响因子：
--
通讯作者：
Grimm J
中科院分区：
文献类型：
--
作者：
Ruggiero A;Holland JP;Lewis JS;Grimm J
新型多模态显像剂和技术的发展代表了当前医学成像科学领域的研究前沿。然而，核断层扫描与光学技术的结合尚未建立。在这里，我们报告了使用放射性药物衰变的固有光学发射进行体内肿瘤的切伦科夫发光成像（CLI），并将结果与一致性免疫pet研究获得的结果相关联。体外模拟实验验证了一系列放射性核素的可见光发射，包括正电子发射体18F、64Cu、89Zr和124I；β发射器131我;α粒子发射器225Ac用于CLI。采用新型放射标记单克隆抗体89zr -去铁胺B-[DFO-J591]用于前列腺特异性膜抗原（PSMA）的免疫pet表达，将观察到的CLI信号与免疫pet图像和生物分布研究共登记和关联。幻影研究证实，使用标准光学成像设备，可以从一系列正电子、β和α发射放射性核素中观察到切伦科夫辐射。光发射强度随时间的变化与放射性核素衰变一致，并且还发现与活性浓度和测量的PET信号（每克注射剂量百分比）呈线性相关。在携带psma阳性皮下LNCaP肿瘤的雄性严重联合免疫缺陷小鼠体内进行的研究表明，通过免疫pet和CLI可以观察到89Zr-DFO-J591的肿瘤特异性摄取。光学和免疫pet信号强度随时间从24小时增加到96小时，生物分布研究发现与这两种成像方式密切相关。据我们所知，这些研究首次对CLI进行定量评估，用于测量体内放射性示踪剂的摄取。核层析成像和放射治疗中常见的许多放射性核素都有可能用于CLI。CLI的价值在于它能够成像既不发射正电子也不发射γ射线的放射性核素，因此不适合与目前的核成像方式一起使用。切伦科夫辐射发射的光学成像显示出良好的前景，作为一种潜在的新的成像方式，用于快速，高通量的放射性药物筛选
The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography with optical techniques has yet to be established. Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies. In vitro phantom studies were used to validate the visible light emission observed from a range of radionuclides including the positron emitters 18F, 64Cu, 89Zr, and 124I; β-emitter 131I; and α-particle emitter 225Ac for potential use in CLI. The novel radiolabeled monoclonal antibody 89Zr-desferrioxamine B-[DFO-J591 for immuno-PET of prostate-specific membrane antigen (PSMA) expression was used to coregister and correlate the CLI signal observed with the immuno-PET images and biodistribution studies. Phantom studies confirmed that Cerenkov radiation can be observed from a range of positron-,β-, and α-emitting radionuclides using standard optical imaging devices. The change in light emission intensity versus time was concordant with radionuclide decay and was also found to correlate linearly with both the activity concentration and the measured PET signal (percentage injected dose per gram). In vivo studies conducted in male severe combined immune deficient mice bearing PSMA-positive, subcutaneous LNCaP tumors demonstrated that tumor-specific uptake of 89Zr-DFO-J591 could be visualized by both immuno-PET and CLI. Optical and immuno-PET signal intensities were found to increase over time from 24 to 96 h, and biodistribution studies were found to correlate well with both imaging modalities. These studies represent the first, to our knowledge, quantitative assessment of CLI for measuring radiotracer uptake in vivo. Many radionuclides common to both nuclear tomographic imaging and radiotherapy have the potential to be used in CLI. The value of CLI lies in its ability to image radionuclides that do not emit either positrons or γ-rays and are, thus, unsuitable for use with current nuclear imaging modalities. Optical imaging of Cerenkov radiation emission shows excellent promise as a potential new imaging modality for the rapid, high-throughput screening of radiopharmaceuticals
登录
查看更多内容
影响因子：
56.9
作者：
McDevitt, MR;Ma, DS;Scheinberg, DA
通讯作者：
Scheinberg, DA
影响因子：
9.3
作者：
Dijkers, Eli C. F.;Kosterink, Jos G. W.;Lub-de Hooge, Marjolijn N.
通讯作者：
Lub-de Hooge, Marjolijn N.
影响因子：
3.7
作者：
Holland JP;Caldas-Lopes E;Divilov V;Longo VA;Taldone T;Zatorska D;Chiosis G;Lewis JS
通讯作者：
Lewis JS
影响因子：
11.5
作者：
Ballangrud, ÅM;Yang, WH;Sgouros, G
通讯作者：
Sgouros, G
DOI：
10.1007/s00259-006-0160-0
发表时间：
2006-11-01
影响因子：
9.1
作者：
Perk, Lars R.;Visser, Otto J.;van Dongen, Guus A. M. S.
通讯作者：
van Dongen, Guus A. M. S.